601 results on '"Caron, Huib N."'
Search Results
2. Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients
3. Supplementary Data from International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer
4. Data from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma
5. Supplemental Figures 1 and 2 from Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution
6. Supplementary Materials and Methods from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
7. Supplementary Figure Legends from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
8. Supplementary Table 3 from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma
9. Supplementary Figure 1b from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma
10. Supplementary figures S1-8 from Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
11. Legends from Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution
12. Supplementary Table 1 from Glomerular Function Time Trends in Long-Term Survivors of Childhood Cancer: A Longitudinal Study
13. Supplementary Table 1 from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma
14. Supplemental Table 1 and 2 from Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution
15. Supplementary Figure 4 from Glomerular Function Time Trends in Long-Term Survivors of Childhood Cancer: A Longitudinal Study
16. Supplementary Table 2 from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma
17. Supplementary Figure Legend 1 from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma
18. Supplementary Figure 2 from Glomerular Function Time Trends in Long-Term Survivors of Childhood Cancer: A Longitudinal Study
19. Supplementary Figure 5 from Glomerular Function Time Trends in Long-Term Survivors of Childhood Cancer: A Longitudinal Study
20. Supplementary Figure 3 from Glomerular Function Time Trends in Long-Term Survivors of Childhood Cancer: A Longitudinal Study
21. Supplementary Figure 1 from Glomerular Function Time Trends in Long-Term Survivors of Childhood Cancer: A Longitudinal Study
22. Supplementary Table 4 from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma
23. MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
24. Risk of Symptomatic Stroke After Radiation Therapy for Childhood Cancer: A Long-Term Follow-Up Cohort Analysis
25. Neurofeedback ineffective in paediatric brain tumour survivors: Results of a double-blind randomised placebo-controlled trial
26. MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
27. Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia
28. Valvular Abnormalities Detected by Echocardiography in 5-Year Survivors of Childhood Cancer: A Long-Term Follow-Up Study
29. Dose-Effect Relationships for Adverse Events After Cranial Radiation Therapy in Long-term Childhood Cancer Survivors
30. Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth
31. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
32. MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis
33. Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids
34. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression
35. The use of equivalent radiation dose in the evaluation of late effects after childhood cancer treatment
36. Inactivation of CDK2 Is Synthetically Lethal to MYCN Over-Expressing Cancer Cells
37. Mek Inhibition Causes BIM Stabilization and Increased Sensitivity to BCL-2 Family Member Inhibitors in RAS-MAPK-Mutated Neuroblastoma
38. Evaluation of Late Adverse Events in Long-Term Wilms' Tumor Survivors
39. Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and Topotecan
40. Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma
41. The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
42. Toxicity of upfront 131I-metaiodobenzylguanidine (131I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
43. High prevalence of early hypothalamic-pituitary damage in childhood brain tumor survivors: Need for standardized follow-up programs
44. Evaluation of a patient information website for childhood cancer survivors
45. International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer
46. International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer
47. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
48. Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma
49. Prevalence of congenital heart defects in neuroblastoma patients: a cohort study and systematic review of literature
50. Prevalence and patterns of morphological abnormalities in patients with childhood cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.